Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...
Neoleukin is a biopharmaceutical company creati...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Harvard Bioscience is a global developer, manufacturer and marketer of a broad ran...
Harvard Bioscience is a global developer, manuf...
We are a fully integrated biopharmaceutical company focused on the development and...
We are a fully integrated biopharmaceutical com...
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
Join the National Investor Network and get the latest information with your interests in mind.